Cancer survivors may carry hidden aging markers that raise disease risk

NCT ID NCT07114614

Recruiting now Knowledge-focused Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study will compare levels of fatty acid binding proteins and cellular aging markers in 120 cancer survivors versus people who never had cancer. Researchers want to see if these markers are higher in survivors and linked to conditions like diabetes and high blood pressure. Participants will provide blood samples, and no treatment is given.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify biomarkers that predict chronic disease risk in cancer survivors, potentially guiding future preventive care.
What could go wrong: This is an observational study with no treatment being tested. It is early-stage research, and findings may not lead to direct clinical changes or apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer structural epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARKER; STRUCTURAL

Contacts and locations

Locations

Case Comprehensive Cancer Center, UH Rainbow Babies & Children's Hospital
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.